In vitro and preclinical assessment of an intranasal spray formulation of parathyroid hormone PTH 1-34 for the treatment of osteoporosis.

No abstract is available for this paper.

• Publication year

  2018

• Venue

  International journal of pharmaceutics

• Publication date

  2018-01-15

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/j.ijpharm.2017.10.029PMID 29038066
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A materials science vision of extracellular matrix mineralization

  2016cited by this paper
• The effect of parathyroid hormone and teriparatide on fracture healing

  2015cited by this paper
• Intranasal formulations: promising strategy to deliver vaccines

  2014cited by this paper
• Intranasal delivery of systemic-acting drugs: small-molecules and biomacromolecules.

  2014cited by this paper
• II. Needle phobia: a psychological perspective.

  2014cited by this paper
• Developments in human growth hormone preparations: sustained-release, prolonged half-life, novel injection devices, and alternative delivery routes

  2014cited by this paper
• Established and forthcoming drugs for the treatment of osteoporosis

  2014cited by this paper
• Mechanism of Mucosal Permeability Enhancement of CriticalSorb® (Solutol® HS15) Investigated In Vitro in Cell Cultures

  2014cited by this paper
• PTH 1-34 loaded thiolated chitosan nanoparticles for osteoporosis: oral bioavailability and anabolic effect on primary osteoblast cells.

  2014cited by this paper
• Successful treatment of nonunion with teriparatide after failed ankle arthrodesis for Charcot arthropathy

  2013cited by this paper
• Pharmacokinetics of Oral Recombinant Human Parathyroid Hormone [rhPTH(1–31)NH2] in Postmenopausal Women with Osteoporosis

  2013cited by this paper
• Improvements in hip trabecular, subcortical, and cortical density and mass in postmenopausal women with osteoporosis treated with denosumab.

  2013cited by this paper
• In vitro and in vivo evaluation of osteoporosis therapeutic peptide PTH 1-34 loaded pegylated chitosan nanoparticles.

  2013cited by this paper
• Established and forthcoming drugs for the treatment of osteoporosis.

  2013cited by this paper
• Improved adherence with PTH(1–84) in an extension trial for 24 months results in enhanced BMD gains in the treatment of postmenopausal women with osteoporosis

  2013cited by this paper
• Evaluation of the efficacy, safety and pharmacokinetic profile of oral recombinant human parathyroid hormone [rhPTH(1-31)NH(2)] in postmenopausal women with osteoporosis.

  2013cited by this paper
• Update on bone anabolics in osteoporosis treatment: rationale, current status, and perspectives.

  2012cited by this paper
• A systematic review of hip fracture incidence and probability of fracture worldwide

  2012cited by this paper
• The impact of teriparatide adherence and persistence on fracture outcomes

  2012cited by this paper
• Nasal drug delivery - recent developments and future prospects.

  2012cited by this paper
• CriticalSorb™: enabling systemic delivery of macromolecules via the nasal route

  2012cited by this paper
• CriticalSorb™ Promotes Permeation of Flux Markers Across Isolated Rat Intestinal Mucosae and Caco-2 Monolayers

  2012cited by this paper
• Nasal drug delivery devices: characteristics and performance in a clinical perspective—a review

  2012cited by this paper
• The single dose pharmacokinetic profile of a novel oral human parathyroid hormone formulation in healthy postmenopausal women.

  2012cited by this paper
• Effects of morning vs. evening teriparatide injection on bone mineral density and bone turnover markers in postmenopausal osteoporosis

  2012cited by this paper
• Randomized Teriparatide [human parathyroid hormone (PTH) 1-34] Once-Weekly Efficacy Research (TOWER) trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk.

  2012cited by this paper
• CriticalSorb: a novel efficient nasal delivery system for human growth hormone based on Solutol HS15.

  2012cited by this paper
• Adherence and persistence with teriparatide among patients with commercial, Medicare, and Medicaid insurance

  2011cited by this paper
• Determinants of fracture risk in a UK-population-based cohort of older women: a cross-sectional analysis of the Cohort for Skeletal Health in Bristol and Avon (COSHIBA)

  2011cited by this paper
• Denosumab improves density and strength parameters as measured by QCT of the radius in postmenopausal women with low bone mineral density.

  2010cited by this paper
• Pharmacokinetics of Teriparatide (rhPTH[1–34]) and Calcium Pharmacodynamics in Postmenopausal Women with Osteoporosis

  2010cited by this paper
• Excess mortality following hip fracture: a systematic epidemiological review

  2009cited by this paper
• Intranasal drug delivery: how, why and what for?

  2009cited by this paper
• Persistence with teriparatide in postmenopausal osteoporosis; impact of a patient education and follow-up program: the French experience

  2009cited by this paper
• Intermittent PTH stimulates periosteal bone formation by actions on post-mitotic preosteoblasts.

  2009cited by this paper
• Compliance with osteoporosis drug therapy and risk of fracture

  2007cited by this paper
• Characterisation of ligand binding to the parathyroid hormone/parathyroid hormone‐related peptide receptor in MCF7 breast cancer cells and SaOS‐2 osteosarcoma cells

  2007cited by this paper
• Daily nasal spray of hPTH(1–34) for 3 months increases bone mass in osteoporotic subjects: a pilot study

  2006cited by this paper
• Continuous PTH and PTHrP Infusion Causes Suppression of Bone Formation and Discordant Effects on 1,25(OH)2Vitamin D

  2005cited by this paper
• In vitro and in vivo activities of C-terminally truncated PTH peptides reveal a disconnect between cAMP signaling and functional activity.

  2004cited by this paper
• Challenges for the oral delivery of macromolecules

  2003cited by this paper
• Internalization Determinants of the Parathyroid Hormone Receptor Differentially Regulate β-Arrestin/Receptor Association*

  2002cited by this paper
• Parathyroid hormone receptor recycling: role of receptor dephosphorylation and beta-arrestin.

  2002cited by this paper
• Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis.

  2001cited by this paper
• Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone.

  1999cited by this paper
• Matrix deposition by a calcifying human osteogenic sarcoma cell line (SAOS-2).

  1995cited by this paper
• Characterization of a human osteosarcoma cell line (Saos-2) with osteoblastic properties.

  1987cited by this paper

• Pharmacokinetics of intranasal drugs, still a missed opportunity?

  2024cites this paper
• 鼻腔药物递送的影响因素和提高递送效率的设计策略

  2023cites this paper
• Recent Advances in Teriparatide Delivery by-virtue-of Novel Drug Delivery Approaches for the Management of Osteoporosis.

  2023cites this paper
• In Vivo Evaluation of Almotriptan malate Formulation through Intranasal Route for the Treatment of Migraine: Systematic Development and Pharmacokinetic Assessment

  2023cites this paper
• Chitosan-based Formulation for Bone Health: A Review

  2023cites this paper
• Paclitaxel Delivery to the Brain for Glioblastoma Treatment

  2023cites this paper
• A Comprehensive Review of Advanced Nasal Delivery: Specially Insulin and Calcitonin.

  2023cites this paper
• A Narrative Review on Non-Invasive Drug Delivery of Teriparatide: A Ray of Hope.

  2023cites this paper
• Effect of Different Absorption Enhancers on the Nasal Absorption of Nalmefene Hydrochloride

  2022cites this paper
• Nose to brain delivery of melatonin lipidic nanocapsules as a promising post-ischemic neuroprotective therapeutic modality

  2022influential citation
• Nanotechnologies for the delivery of biologicals: historical perspective and current landscape.

  2021cites this paper
• Target specific tight junction modulators.

  2021cites this paper
• Development and in vivo evaluation of intranasal formulations of parathyroid hormone (1-34)

  2021cites this paper
• Increased antitumor efficacy of ginsenoside Rh2 via mixed micelles: in vivo and in vitro evaluation

  2020cites this paper
• The Role of Chronic Inflammatory Bone and Joint Disorders in the Pathogenesis and Progression of Alzheimer's Disease

  2020cites this paper
• Effect of Cinacalcet on the Redox Status of Albumin in Secondary Hyperparathyroidism Patients Receiving Hemodialysis.

  2020cites this paper
• Current Applications of Pharmaceutical Biotechnology

  2020cites this paper
• Transmucosal Absorption Enhancers in the Drug Delivery Field

  2019cites this paper
• Hormones, Blood Products, and Therapeutic Enzymes.

  2019cites this paper
• Nasal Administration and Plasma Pharmacokinetics of Parathyroid Hormone Peptide PTH 1-34 for the Treatment of Osteoporosis

  2019influential citation
• Amphiphilic block copolymers in drug delivery: advances in formulation structure and performance

  2018cites this paper
• The guiding role of bone metabolism test in osteoporosis treatment.

  2018cites this paper